Anti-IL-5 Antibody (Reslizumab)
Catalog No.
F2108
Anti-IL-5 Antibody (Reslizumab)
Featured Products
Reslizumab is a humanized monoclonal antibody that is primarily used to treat severe eosinophilic asthma. It reduces the number and activity of eosinophils by targeting and neutralizing interleukin-5 (IL-5). Reslizumab is derived from expression in mammalian cells through recombinant DNA technology. Its composition includes an antibody structure of the IgG4 subtype. Reslizumab inhibits the growth, differentiation and survival of eosinophils by blocking the binding of IL-5 to its receptor, thereby alleviating asthma symptoms.
Dry ice
241473-69-8
-80°C
2 years
Liquid
1 mg/mL
For reconstitution, we recommend adding sterile, distilled water to achieve a final antibody concentration. Gently shake it to solubilize the protein completely. Do not vortex.
CHO
Cinqair, Cinqaero, Sch 55700
100 mM Pro 20 mM Arg pH 5.0.
Human
Unconjugated
Monoclonal
Protein A
IgG4
ELISA, FACS, Kinetics, Functional assay, Animal Model
IL-5
Please avoid freeze-thaw cycles.